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3 
The expression of IL-21 is promoted by MEKK4 in malignant T cells and 40 
associated with increased progression risk in cutaneous T-cell lymphoma 41 
 42 
Signaling through Interleukin-2 (IL-2) receptor gamma (IL-2Rg) via the cytokines IL-43 
2, IL-4, IL-7, IL-15, and IL-21 has been implicated in the pathogenesis of cutaneous 44 
T-cell lymphomas (CTCL) (Marzec et al., 2008). Extensive research has documented 45 
that IL-2, IL-7, and IL-15 stimulate proliferation of malignant T cells, while IL-4 is 46 
known to promote a Th2 type inflammatory response within the affected skin. In 47 
contrast, the role of IL-21 remains unclear since IL-21 was shown to exert both pro- 48 
and anti-tumorigenic responses. On the one hand, IL-21 stimulates anti-tumor 49 
cytotoxic T cells and NK cells, which leads to inhibition of tumor growth in vivo in a 50 
number of cancer models (Sondergaard et al., 2007; Spolski and Leonard, 2014), 51 
while on the other hand, it activates the proto-oncogene Signal Transducer and 52 
Activator of Transcription (STAT3)(Marzec et al., 2008), which ultimately promotes 53 
expression of pro-inflammatory cytokines and survival factors in malignant T cells 54 
(Sommer et al., 2004). 55 
 56 
Interestingly, IL-21 itself is also a target of STAT3 suggesting the existence of a 57 
vicious circle, where IL-21 stimulates STAT3 activation, which in turn up-regulates 58 
IL-21 expression (van der Fits et al., 2012). However, IL-21 expression was only 59 
partly reduced following inhibition of STAT3 signaling (van der Fits et al., 2012) and 60 
IL-21 blockade did not block STAT3 activation (van der Fits et al., 2014) indicating 61 
that other pathways are also involved in IL-21 expression in malignant T cells.  62 
The Mitogen-Activated Protein (MAP) KinaseKinaseKinase (MEKK4/ MAP3K4) 63 
was recently shown to drive IL-21 expression in CD4+ T cells from patients with 64 
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Systemic Lupus Erythematosus (SLE) (Lee et al., 2014), but this has not been 65 
documented in CTCL. Yet, a downstream MAP Kinase, p38, is constitutive active in 66 
this malignancy and associated with disease progression (Bliss-Moreau et al., 2015).  67 
 68 
To elucidate this signaling pathway we addressed whether MEKK4 and p38 were 69 
involved in the regulation of IL-21 mRNA expression in patient-derived malignant T 70 
cells lines. As shown in Fig. 1A, siRNA-mediated inhibition of MEKK4 resulted in a 71 
significant inhibition of MEKK4 (Fig. 1A, left) and IL-21 mRNA expression (Fig. 72 
1A, right) providing the evidence that MEKK4 promotes IL-21 expression in 73 
malignant T cells. As expected, siRNA-mediated knock down of STAT3 inhibited IL-74 
21 expression whereas STAT5 knock down had no effect (Fig. 1B). This observation 75 
is consistent with previous findings that IL-21 is a STAT3 target gene in malignant T 76 
cells. Importantly, STAT3 siRNA had no inhibitory effect on the expression of 77 
MEKK4 indicating that MEKK4 is not a down-stream effector of STAT3 (Fig. 1B).  78 
 79 
Our findings further revealed that MEKK4 regulates STAT3 phosphorylation. 80 
Specifically, siRNA-mediated knock down of MEKK4 resulted in a decrease in serine 81 
phosphorylation of STAT3 as judged by Western Blot analysis using a phosphoserine 82 
(P-ser727) specific antibody (Fig. 1C, left), whereas the total amount of STAT3 83 
protein was not decreased (Fig. 1C, right). As expected, IL-21 mRNA expression was 84 
also inhibited by this treatment (Fig. 1C, right). Importantly, a dual knock down of 85 
STAT3 and MEKK4 significantly inhibited IL-21 expression, but to no greater extend 86 
than the inhibition of STAT3 or MEKK4 alone (Fig. 1C) implying that both 87 
treatments target the same pathway and that ser727 phosphorylation is required for 88 
STAT3- mediated IL-21 transcription. Thus, these findings provide evidence for a 89 
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link between MEKK4 signaling and STAT3-S727 serine phosphorylation and suggest 90 
that MEKK4 augments IL-21 expression via this mechanism. Notably, increased 91 
STAT3 serine phosphorylation at residue S727 was previously shown to enhance 92 
transcriptional activity of STAT3 (Zhang et al., 1995).  93 
 94 
The p38 MAP Kinase induces serine-727 phosphorylation of STAT3 and is a well-95 
established down-stream effector of MEKK4 (Platanias, 2003). Hence, we next 96 
addressed the role of p38 in the regulation of IL-21 expression in malignant T cells. 97 
To achieve this, we utilized an inhibitor of p38 (SB203580), which blocks IL-2 98 
induced serine phosphorylation of STAT3 (Gollob et al., 1999). As shown in Fig. 1D, 99 
SB203580 induced a dose-dependent inhibition of IL-21 expression indicating that 100 
p38 indeed promoted the expression of IL-21. Essentially similar results were 101 
obtained in two independent experiments using primary malignant T cells (>90% pure 102 
as judged from TCR-Vb staining) isolated from peripheral blood from a Sezary 103 
Syndrome patient (Fig 1D right). Recently, Aurora kinases A and B were shown to be 104 
highly overexpressed and activated in CTCL skin lesions (Humme et al., 2015). As 105 
p38 is a down-stream effector of Aurora kinases in other cancers, it is tempting to 106 
speculate that Aurora kinases are involved in IL-21 expression by malignant T cells.  107 
 108 
Although it is well established that malignant T cells express IL-21 (Marzec et al., 109 
2008; van der Fits et al., 2012), the pathological and clinical relevance of this 110 
expression remains unclear. In a recent gene expression analysis and 11 year follow-111 
up on the Boston cohort of CTCL patients, Litvinov et al (Litvinov et al., 2015) 112 
documented that IL-21 and IL-21R mRNA expression were highly increased in poor 113 
prognosis patient clusters. However, this analysis did not analyze the prognostic value 114 
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of specific genes. Therefore, we analyzed for expression of IL-21 mRNA in relation 115 
to disease progression in the Boston cohort of CTCL (N=60) patients and compared 116 
IL-21 expression between CTCL lesional skin, normal skin samples derived from 117 
healthy volunteers (N=6), and benign inflammatory dermatoses that often mimic this 118 
malignancy (e.g., psoriasis, pityriasis rubra pilaris and chronic eczema) (N=12) 119 
(Litvinov et al., 2010). All patients were enrolled in the IRB-approved study protocol 120 
with written, informed consent in accordance with the Declaration of Helsinki 121 
(Litvinov et al., 2015).  122 
 123 
 As presented, in Table S1, IL-21 was expressed in early and advanced stages of 124 
CTCL, therefore, suggesting that IL-21 is not simply a surrogate marker for advanced 125 
disease. IL-21 was also increased in skin samples from CTCL patients compared to 126 
benign inflammatory dermatoses and healthy controls (Fig. 2A). Importantly, IL-21 127 
expression was associated with overall disease progression in CTCL patients, defined 128 
as the advancement to the next clinical stage and/or death (Figure 2B). Moreover, IL-129 
21 positivity was associated with increased disease-related mortality (Figures 2C). 130 
Furthermore, in our study 19 stage I patient were IL-21- and 18 Stage I patients were 131 
IL-21+. Hence, we performed Kaplan-Meier analysis of disease progression from 132 
stage I to advanced (≥IIB) stages and/or death. This analysis further confirmed that 133 
IL-21 expression is associated with progressive disease even for early stages of CTCL 134 
(Figures 2D). These results suggest that there might be an association between IL-21 135 
expression/signaling and disease progression. Notably, p38 and STAT3 activity were 136 
also shown to correlate with disease progression (Bliss-Moreau et al., 2015) thereby 137 
further highlighting the clinical relevance of our in-vitro findings in malignant T cell 138 
lines.  139 
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In conclusion, we show that IL-21 expression in malignant T-cells is augmented via 140 
MEKK4/p38-mediated serine-727 phosphorylation of STAT3 in-vitro, and that IL-21 141 
expression is associated with progressive disease.  142 
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Figure legends  223 
Figure 1. Map3K4 promotes the expression of IL-21 in malignant T-cells. 224 
A: MEKK4 and IL21 mRNA expression in malignant T-cell lines obtained from 225 
different subtypes of cutaneous T cell lymphoma (MF, SS, and CD30+ anaplastic 226 
large T cell lymphoma) after treatment with siRNA against MEKK4 (N=3). B: 227 
STAT3, STAT5 and Actin (as control) protein expression and MEKK4 and IL21 228 
mRNA expression in two different malignant T-cell lines after treatment with 229 
siRNA targeting STAT3 and STAT5 mRNAs (N=3). C: Total STAT3, p(ser727)-230 
STAT3, actin (as control) protein expression and MEKK4 and IL-21 mRNA 231 
expression in the malignant T-cell line MAC2a after treatment with siRNA 232 
targeting MEKK4,  STAT3 or combination of MEKK4 and STAT3 (N=2). D & E: IL-233 
21 mRNA expression following a treatment with p-38 inhibitor of a CD30+ 234 
malignant T cell line, MAC2A, derived from a nonregressing tumor of a patient 235 
who had progressed from lymphomatoid papulosis to systemic anaplastic large 236 
cell lymphoma (Levi et al., 2000)  (N=3)(D) and primary malignant T-cells 237 
isolated from peripheral blood from Sezary Syndrome (N=2)(E).  238 
 239 
Figure 2. IL-21 is associated with disease progression in CTCL.  240 
A: Relative IL-21 mRNA expression in patients with CTCL, benign inflammatory 241 
dermatoses or healthy volunteers. B-D: Kaplan-Meier survival curves comparing 242 
CTCL patients, with or without IL-21 mRNA expression. (B) CTCL patient overall 243 
disease progression based on their IL-21 expression status (“progression” 244 
defined as progression to a higher clinical stage and/or death, p=0.011). (C) 245 
CTCL patient disease-specific survival based on their IL-21 expression status, 246 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
12 
p=0.050. (D) Progression of patients with stage I disease to more advance stages 247 
(i.e., stage ≥II) based on their IL-21 expression status, p=0.023. 248 
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